Proteon Therapeutics Initiates Phase 3 Clinical Study of PRT-201 in Patients with Chronic Kidney Disease Undergoing Surgical Placement of an Arteriovenous Fistula for Hemodialysis

Proteon Therapeutics Inc., a privately held biopharmaceutical company developing novel, first-in-class pharmaceuticals to address the critical medical needs of patients with kidney and vascular diseases, announced today that the first patient has been trea... [more]

View complete Press Release article